MDT-AP-2388
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 135.60000000000002
- os_event
- false
- age_years
- 2.2
- sex
- M
- new_clusters
- C2
- umap1_2d
- 2.654666377
- umap2_2d
- 0.554864847
- umap1_3d
- -0.439719021
- umap2_3d
- -2.575075696
- umap3_3d
- -1.284531795
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.540
- MYC_TARGETS_V2+0.530
- E2F_TARGETS+0.520
- DNA_REPAIR+0.470
- OXIDATIVE_PHOSPHORYLATION+0.470
- G2M_CHECKPOINT+0.410
- UNFOLDED_PROTEIN_RESPONSE+0.220
- FATTY_ACID_METABOLISM+0.200
- PEROXISOME+0.200
- ADIPOGENESIS+0.170
Top 10 suppressed
- INFLAMMATORY_RESPONSE-0.470
- ALLOGRAFT_REJECTION-0.440
- INTERFERON_GAMMA_RESPONSE-0.440
- INTERFERON_ALPHA_RESPONSE-0.420
- IL6_JAK_STAT3_SIGNALING-0.410
- COMPLEMENT-0.380
- TNFA_SIGNALING_VIA_NFKB-0.330
- KRAS_SIGNALING_UP-0.320
- APICAL_SURFACE-0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 176e93be-1ae5-43f2-a0b5-17f31695e679 | — | — | 0.927 |
| 2 | ERR2208894 | — | — | 0.926 |
| 3 | SRR10899994 | — | — | 0.923 |
| 4 | SRR975602 | — | — | 0.917 |
| 5 | MDT-AP-0756 | Med | Medulloblastoma | 0.916 |
| 6 | fea46737-a2b3-49d4-8358-d0737546b6da | — | — | 0.909 |
| 7 | TCGA-85-8070-01A-11R-2247-07 | — | cohortSQ2 | 0.908 |
| 8 | BS_TZVFR600 | Med | Medulloblastoma | 0.907 |
| 9 | TCGA-XF-A9ST-01A-11R-A42T-07 | — | — | 0.907 |
| 10 | 20120209.TNBC | — | E | 0.906 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.540 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.530 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.520 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.470 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.470 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.410 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.220 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.170 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.160 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.150 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.130 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.110 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.090 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.040 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.030 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.010 | Inavolisib | — uncovered |